Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720378 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
A Phase 1 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04720378 is a Phase 1 study that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 12 participants.
The verdict
NCT04720378, a Phase 1 study, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
Interventions
- BIOLOGICAL ST266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-30 |
| Est. Completion | 2022-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720378
The ClinicalTrials.gov registry entry for NCT04720378 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noveome Biotherapeutics, formerly Stemnion, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ST266 is the first listed.
NCT04720378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04720378 about?
NCT04720378 is a clinical study titled "Safety and Tolerability Study of IV ST266 in COVID-19 Subjects". The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
What is the current status of trial NCT04720378?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-30. Estimated completion is 2022-05-03.
What interventions are being tested in trial NCT04720378?
The interventions under investigation include: ST266 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04720378?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.